High HPV-51 Prevalence in Invasive Cervical Cancers: Results of a Pre-Immunization Survey in North Sardinia, Italy

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Piana, Andrea ^a   Sotgiu, Giovanni ^a   Cocuzza, Clementina ^b   Musumeci, Rosario ^b   Marras, Vincenzo ^c   Pischedda, Stefania ^a   Deidda, Silvia ^a   Muresu, Elena ^a   Castiglia, Paolo ^a  

^a UNIVERSITY HOSPITAL OF SASSARI   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MIXED INFECTION; OBSERVATIONAL STUDY; PAPILLOMAVIRUS INFECTION; PREVALENCE; RETROSPECTIVE STUDY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; IMMUNIZATION; ITALY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 84878083364     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063395     Document Type: Article

References (34)

1. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre) (2010) Human Papillomavirus and Related Cancers in World. Summary Report 2010. Available: www.who.int/hpvcentre. Accessed 2012 Dec. 21.
2. Faridi R, Zahra A, Khan K, Idrees M, (2011) Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Virol J 8: 269.
3. Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, et al. (2008) Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 100: 513-517.
4. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL, (2011) Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med 53Suppl 1: S12-21.
5. Panatto D, Amicizia D, Trucchi C, Casabona F, Lai PL, et al. (2012) Sexual behaviour and risk factors for the acquisition of human papillomavirus infections in young people in Italy: suggestions for future vaccination policies. BMC Public Health 12: 623.
6. Malagón T, Drolet M, Boily MC, Franco EL, Jit M, et al. (2012) Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12(10): 781-789.
7. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, et al. (2012) Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13(1): 100-110.
8. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, et al. (2010) Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11(11): 1048-1056.
9. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 100B (2011) A Review of Human Carcinogens: Biological Agents. Available: http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-11.pdf. Accessed 2012 Dec 21.
10. Piana A, Sotgiu G, Castiglia P, Pischedda S, Cocuzza C, et al. (2011) Prevalence and type distribution of human papillomavirus infection in women from North Sardinia, Italy. BMC Public Health 11: 785.
11. Agarossi A, Ferrazzi E, Parazzini F, Perno CF, Ghisoni L, (2009) Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy. J Med Virol 81(3): 529-535.
12. Sandri MT, Riggio D, Salvatici M, Passerini R, Zorzino L, et al. (2009) Typing of human papillomavirus in women with cervical lesions: prevalence and distribution of different genotypes. J Med Virol 81(2): 271-277.
13. Gargiulo F, De Francesco MA, Schreiber C, Ciravolo G, Salinaro F, et al. (2007) Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women. Virus Res 125(2): 176-182.
14. Venturoli S, Ambretti S, Cricca M, Leo E, Costa S, et al. (2008) Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment. J Med Virol 80(8): 1434-1440.
15. Steinau M, Patel SS, Unger ER, (2011) Efficient DNA extraction for HPV genotyping in formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 13(4): 377-381.
16. Broccolo F, Chiari S, Piana A, Castiglia P, Dell'Anna T, et al. (2009) Prevalence and viral load of oncogenic human papillomavirus types associated with cervical carcinoma in a population of North Italy. J Med Virol 81(2): 278-87.
17. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, et al. (2012) Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13(1): 100-10.
18. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 199: 926-35.
19. Masia G, Mazzoleni AP, Contu G, Laconi S, Minerba L, et al. (2009) Epidemiology and genotype distribution of human papillomavirus (HPV) in women of Sardinia (Italy). Vaccine 27(Suppl 1): A11-16.
20. Goldman B, Rebolj M, Rygaard C, Preisler S, Ejegod DM, et al. (2013) Patterns of cervical coinfection with multiple human papilloma virus types in a screening population in Denmark. Vaccine 2013 Jan 10.
21. Schmeink C, Massuger L, Lenselink C, Quint W, Witte B, et al. (2012) Prospective follow-up of 2065 young unscreened women to study human papillomavirus incidence and clearance. Int J Cancer 2012 Dec 11.
22. Balbi G, Napolitano A, Giordano F, Capuano S, Manganaro MA, et al. (2012) Role of the association of high-risk HPV identified by real-time PCR in cervical preneoplastic lesions. Eur J Gynaecol Oncol 33(5): 467-471.
23. Mollers M, Boot Hein J, Vriend Henrike J, King Audrey J, van den Broek Ingrid VF, et al. (2013) Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands. Vaccine 31(2): 394-401.
24. Guido M, Tinelli A, De Donno A, Bruno AR, Tagliaferro L, et al. (2013) Prevalence and Distribution of Human Papillomavirus Genotype in South Eastern Italy, in the Period 2006-2011: Implications For Intervention. Curr Pharm Des 19(8): 1498-1507.
25. Mollers M, Scherpenisse M, van der Klis FR, King AJ, van Rossum TG, et al. (2012) Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination. Cancer Epidemiol 36(6): 519-524.
26. Mane A, Nirmalkar A, Risbud AR, Vermund SH, Mehendale SM, et al. (2012) HPV genotype distribution in cervical intraepithelial neoplasia among HIV-infected women in Pune, India. PLoS One 7(6): e38731.
27. Zhang HY, Tiggelaar SM, Sahasrabuddhe VV, Smith JS, Jiang CQ, et al. (2012) HPV prevalence and cervical intraepithelial neoplasia among HIV-infected women in Yunnan Province, China: a pilot study. Asian Pac J Cancer Prev 13(1): 91-6.
28. Sahasrabuddhe VV, Mwanahamuntu MH, Vermund SH, Huh WK, Lyon MD, et al. (2007) Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Cancer 96(9): 1480-3.
29. Xi LF, Touré P, Critchlow CW, Hawes SE, Dembele B, et al. (2003) Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35 years of age. Int J Cancer 103(6): 803-9.
30. Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, et al. (2009) Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 125(9): 2151-8.
31. Schiffman M, Wacholder S, (2012) Success of HPV vaccination is now a matter of coverage. Lancet Oncol. 13(1): 10-12.
32. Lipsitch M, (1997) Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci USA 94: 6571-6576.
33. Merikukka M, Kaasila M, Namujju PB, Palmroth J, Kirnbauer R, et al. (2011) Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int J Cancer 128(5): 1114-1119.
34. Garnett GP, Waddell HC, (2000) Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol 19(1-2): 101-111.